Breaks Categories: Stock Spotlights

TuesdayFeb 27, 2024 3:14 pm

BioMedNewsBreaks — Clene Inc.’s (NASDAQ: CLNN) CNM-Au8 Aiming to Address Neurodegenerative Diseases from a New Angle

Clene (NASDAQ: CLNN) is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”), Parkinson’s and multiple sclerosis (“MS”). “The company’s lead drug candidate is CNM-Au8, an innovative nanomedicine uniting the principles of physics, chemistry, materials science, and biology to address neurodegenerative diseases from a new angle. Clene uses catalytic boosting of energy metabolism to enable dying neurons to resist the multiple stressors associated with disease, allowing them not only to survive but also to function,” a recent article reads. The article discusses CNM-Au8 development pathways, which…

Continue Reading

WednesdayFeb 21, 2024 3:27 pm

BioMedNewsBreaks — Astrotech Corporation’s (NASDAQ: ASTC) Subsidiary Bringing ‘Game Changer’ Technology in AgLAB MVP

Astrotech’s (NASDAQ: ASTC) subsidiary AgLAB, Inc. has breakthrough mass spectrometry technology in its AgLAB 1000-D2 mass spectrometer and the Maximum Value Process(TM) testing method (“AgLAB MVP”). “AgLAB MVP is designed to improve yields and bottom-line profits for hemp (‘CBD’) and cannabis (‘THC’) producers of CBD-THC oils by up to 30%. Large-scale CBD and THC oil processors use molecular distillation systems (‘MDS’) to produce the valuable oils that are used in lotions, pills, tinctures, and cartridges. Using the AgLAB MVP solution, customers are now able to analyze the oils during processing and make near real-time adjustments that can boost the ending-weight…

Continue Reading

WednesdayFeb 21, 2024 2:20 pm

BioMedNewsBreaks — Longeveron Inc.’s (NASDAQ: LGVN) ELPIS Trial Demonstrates Potential Survival Benefit of Lomecel-B(TM) for HLHS Patients

Longeveron’s (NASDAQ: LGVN) extended long-term follow-up data from the ELPIS I study was presented as a poster at the annual Scientific Sessions of the American Heart Association (“AHA”). “ELPIS I was designed to assess the safety and potential efficacy of intramyocardial injection of Lomecel-B(TM) administered to 10 infants with hypoplastic left heart syndrome (‘HLHS’) during Stage II surgeries at approximately 4 months of age. The study met the primary safety endpoint: no major adverse cardiac events or any treatment-related infections during the first month post-treatment were reported. Moreover, secondary endpoints measured per protocol suggested Lomecel-B injection may improve patient long-term…

Continue Reading

TuesdayFeb 20, 2024 3:17 pm

BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Eyes ‘Rarely Seen’ Clinically Significant Improvement in MS Patients

Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, recently reported new results from a long-term open-label extension (“LTE”) of the VISIONARY-MS trial in participants with stable relapsing multiple sclerosis (“RMS”) totaling nearly three years of follow up. Data from the study show clear overall improvements in vision and cognition for participants treated for nearly three years from randomization, with these results robust and consistent, according to Professor Michael Barnett, Professor of Neurology, Brain and Mind Centre, University of Sydney, and…

Continue Reading

MondayFeb 12, 2024 2:50 pm

BioMedNewsBreaks — Astiva Health Marks Pivotal Phase in Transforming Healthcare Delivery

Astiva Health, a leading healthcare provider that specializes in delivering personalized and comprehensive solutions to diverse communities, was spotlighted as a significant player in the Medicare Advantage Prescription Drug (“MAPD”) sector in a recent episode of the Bell2Bell Podcast. “The episode featured an exclusive interview with Astiva Health’s Co-Founder and CEO Dr. Tri Nguyen, a renowned expert in internal medicine and cardiology. During the interview, Dr. Nguyen discusses Astiva Health’s journey since its inception in 2020 and its expansion plans. He shared insightful details about the company’s expansion to Los Angeles, San Bernardino and Riverside, marking a pivotal phase in…

Continue Reading

WednesdayFeb 07, 2024 1:01 pm

BioMedNewsBreaks – Astrotech Corporation (NASDAQ: ASTC) Introducing Breakthrough Technology, Potential ‘Game Changer’ for the Cannabinoid Industry

Astrotech (NASDAQ: ASTC) is an instrumentation company that is focused on commercializing its proprietary ATi Mass Spectrometer Technology(TM). Its subsidiary, AgLAB Inc., has breakthrough mass spectrometry technology in its AgLAB-1000-D2 mass spectrometer, a ruggedized factory floor analytical instrument designed to quickly and easily analyze complex chemical compounds found in organic plant materials, and the Maximum Value Process(TM) testing method (“AgLAB MVP”). “AgLAB MVP is designed to improve yields and bottom-line profits for hemp (‘CBD’) and cannabis (‘THC’) producers of CBD-THC oils by up to 30%... Using the AgLAB MVP solution, customers are now able to analyze the oils during processing…

Continue Reading

FridayFeb 02, 2024 12:28 pm

BioMedNewsBreaks – Clene Inc.’s (NASDAQ: CLNN) CNM-Au8 Produces ‘Significant and Very Promising Effect’ in Parkinson’s, MS Patients

Clene’s (NASDAQ: CLNN) lead drug candidate CNM-Au8 was the subject of two Phase 2a clinical trials, REPAIR-PD and REPAIR-MS, which evaluated the effects of CNM-Au8 on brain energy metabolite levels in participants with diagnoses of idiopathic Parkinson’s Disease (“PD”) and relapsing Multiple Sclerosis (“MS”), respectively. The REPAIR-PD and REPAIR-MS Phase 2 trials expanded the documented evidence of CNM-Au8’s positive effects demonstrated by in vitro studies, which have shown that the surfaces of the drug candidate’s nanocrystals catalyze the rapid oxidation of NADH to NAD+, increasing the intracellular availability of both NAD+ and ATP. NAD+ supports the synthesis of ATP, the…

Continue Reading

FridayJan 26, 2024 2:41 pm

BioMedNewsBreaks — Astrotech Corporation’s (NASDAQ: ASTC) Pro-Control-1000(TM) Line Poised to Help Manufacturers Improve Profits, Yields

Astrotech (NASDAQ: ASTC ), an instrumentation company focused on commercializing its proprietary ATi Mass Spectrometer Technology(TM) that is now used in airports and agriculture applications throughout the world, continues to expand its technology into new markets. “Astrotech has announced the introduction of its newest Pro-Control-1000(TM) product line of instrumentation designed to improve chemical manufacturing efficiencies. Astrotech is also announcing the creation of its newest wholly owned subsidiary, Pro-Control, Inc., that has been awarded an exclusive ATi field-of-use license for worldwide chemical manufacturing and process control applications. The Pro-Control-1000(TM) mass-spec is ideally suited for use in the chemical manufacturing industry due…

Continue Reading

FridayJan 26, 2024 1:43 pm

BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) Dedicated to Enhancing Quality of Life for Individuals Living with ASD

PaxMedica (NASDAQ: PXMD) recently released an insightful video detailing the outcomes of its Phase 2 study on autism spectrum disorder (“ASD”), initially published in the Annals of General Psychiatry. “This pivotal video highlights the research led by Chief Medical Officer Dr. David Hough and a team of ASD experts, and the potential of low-dose suramin intravenous infusions as a breakthrough treatment for ASD… Focused on evaluating the efficacy and safety of suramin intravenous infusions, the study’s 10 mg/kg suramin arm displayed promising results in improving core symptoms of ASD, showcasing statistically significant improvements in the Clinical Global Impressions-Improvement (‘CGI-I’) scale…

Continue Reading

WednesdayJan 24, 2024 3:19 pm

BioMedNewsBreaks — Why Sigyn Therapeutics Inc. (SIGY) Is ‘One to Watch’

Sigyn Therapeutics (OTCQB: SIGY) is a development-stage medical technology company whose therapeutic candidates include Sigyn Therapy(TM), the ImmunePrep(TM) platform, ChemoPrep(TM), and ChemoPure(TM). “The company is advancing Sigyn Therapy to treat pathogen-associated inflammatory disorders that are not addressed with FDA-approved drugs. Candidate treatment indications include community-acquired pneumonia, drug-resistant virus and bacterial infections, endotoxemia, and sepsis, which is the leading cause of hospital deaths in the United States... In vitro studies have demonstrated the ability of Sigyn Therapy to eliminate life-threatening pathogen and inflammatory disease targets from human blood plasma… Sigyn designed the ImmunePrep platform to leverage the use of therapeutic antibodies…

Continue Reading